Tag Archives: debt ceiling
Dear Research Advocate:
What does the current political impasse in Washington have in common with deadly or disabling diseases? They will not cure themselves, and the harm escalates until the “patient” gets expert treatment. There is no place for miracle cures or wishful thinking. The solution isn’t what a given individual or party wants it to be, it’s what solves the problem. Right now, it’s by no means clear what or who will solve the problems — which now include the debt ceiling as well as the lack of funding to run the government. Fasten your seat belts for more turbulence between now and October 17th.
You may have heard that the House passed a bill yesterday to fund NIH, along with several other stand-alone appropriation bills (funding it at an unacceptably low level, I might add — below FY12 levels). Beyond the fact that this piecemeal, slow-walking avoidance tactic of finding a solution to the government shutdown is dead on arrival in the Senate and the White House, this “Sophie’s Choice,” cherry-picking approach to better health has no place in a functioning research and innovation ecosystem, and we spoke out against it. That said, it was gratifying that NIH was singled out as publicly popular and good to see the possibility of new champions emerging who recognize the importance of NIH funding during the floor debate on the bill. But make no mistake, had we and other advocates supported this ill-conceived measure, we would have been supporting the decline of science in this nation. Continue reading →
Dear Research Advocate,
With all the conversation about the debt ceiling and tax and entitlement reform, it may surprise you to know that an additional topic is on many minds. A wide majority of Americans, 72%, say the new Congress and the president should take action to expand medical research within the first 100 days of the new legislative session. See this and more in America Speaks, Volume 13, a compilation of national poll data providing insights into public sentiment on key research-related issues. See our press release and download the full Poll Data Summary. These polling results are designed to be used in your advocacy and outreach!
Among the growing number of issues that need to be resolved by the new Congress is the medical device tax, which could send research jobs overseas and shrink a critical segment of our innovation economy. In The Hill, Rep. Bob Latta (R-OH) writes about the consequences the tax could have on the medical device industry, including the possibility of a massive decline in R&D investment. As our economy recovers, policy makers must better incentivize R&D investment to keep our nation competitive and ensure that companies are continuing to invest in life-saving research.
More on the first 100 days: As you know, the sequestration deadline has been moved two months, with another delay possible, and there is talk of other cuts to discretionary spending. The delay is terribly frustrating for those planning research investment and sends a very negative message to young scientists planning a career, but it does buy us more time to make our case. The Washington Post published an op-ed by three Washington, DC, institutional members of Research!America that argues compellingly for such funding. Take action now and do two things — collaborate with your local colleagues to write an op-ed for a local publication and send an email to your representatives. Tailor the alert we provide to let them know how cuts could affect your institution and your community.
For those of you in Georgia, the appointment of Rep. Jack Kingston (R-GA) as chairman of the committee that allocates most of the federal funding for biomedical and health research funding presents an important advocacy opportunity. Research!America is helping to facilitate collective action by Georgia institutions, and we would welcome your participation. Please contact Max Bronstein, director of science policy, if you haven’t heard from us yet! Recently, I had the opportunity to discuss Rep. Kingston’s record and prospects for the 113th Congress with Randy Barrett of the ScienceInsider.
Great news! The U.S. Supreme Court issued a decision on behalf of patients and stem cell researchers, effectively bringing to a close the infamous Sherley v. Sebelius case that threatened federal funding for embryonic stem cell research. This decision marks a major victory for the stem cell research cause, but it is critical that all of us remain vigilant; actions at the state level could still curtail embryonic stem cell research. View our press statement on the decision and our updated resource page on stem cell research. We will be talking about the importance of stem cell research when we honor the California Institute for Regenerative Medicine (CIRM) at our upcoming Advocacy Awards dinner. See more about this March 13, 2013, event here.